Skip to main content

Table 3 Summary of antibody–drug conjugates and bispecific antibodies results in diffuse large B cell lymphoma

From: New agents and regimens for diffuse large B cell lymphoma

Target Drug Toxin Combined agents Study Study phase No. Efficacy References
CD19/CD3 Blinatumomab R-chemotherapy NCT
03023878
2 30 ORR 89% [27]
CD19 Coltuximab ravtansine DM4 NCT
01472887
2 61 ORR 44%
CR 15%
[71]
CD19 Loncastuximab tesirine SG3199 NCT
02669017
1 63 ORR 55%
CR 37%
[72]
CD20 MT-3724 SLTA NCT
02361346
1 13 ORR 30%
CR 10%
[57]
CD20 Ibritumomab tiuxetan Yttrium-90 Combined with R as maintenance therapy NCT
00070018
2 33 5-y OS 87%
5-y PFS 82%
[59]
CD20 Tositumomab Iodine-131 R-CHOP NCT
00107380
2 86 ORR 86% CR 61%
2-yPFS69%
2-y OS 77%
[61]
CD20/CD3 RG6026 Obinutuzumab NCT
03075696
1b 28 ORR 48%
CR 43%
[30]
CD20/CD3 Mosunetuzumab NCT
02500407
1/1b 55 ORR 33%
CR 21%
[31]
CD20/CD3 REGN1979 NCT
02290951
1 53 ORR 33%
CR 18%
[32]
CD22 Pinatuzumab vedotin MMAE Rituximab NCT
01691898
2 42 ORR 60% CR 26% [65]
CD22 Inotuzumab ozogamicin Calicheamicin Rituximab NCT
00299494
1/2 42 ORR 74%
2-y EFS 42%
[76]
CD22 Epratuzumab tetraxetan Yttrium-90 R-CHOP NCT
00906841
2 71 2-y EFS
75%
[142]
CD30 Brentuximab vedotin MMAE NCT
02280785
2 12 CR 17%
DCR 50%
[78]
CD30 Brentuximab vedotin MMAE NCT
01421667
2 49 ORR 44%
CR 17%
mPFS: 4 m
[80]
CD74 STRO-001 Maytansinoid warhead NCT
03424603
1 4 ORR 50%
CR 25%
[83]
CD79b Polatuzumab vedotin MMAE Rituximab NCT
01691898
2 39 ORR 54%
CR 21%
mDoR 13.4 m
[65]
CD79b Polatuzumab vedotin MMAE R-CHP/GHP NCT
01992653
1b/2 66 ORR 89%
CR 77%
[64]
  1. MMAE monomethyl auristatin E, AEs adverse events, NEs neurologic events, SLTA Shiga-like toxin-I A1, NHL non-Hodgkin lymphoma, CRS cytokine release syndrome, mDoR median duration of response, EFS event-free survival, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, ORR objective response rate, CR complete response, GHP obinutuzumab, doxorubicin, prednisone